TGIC strengthens academic leadership

The George Institute for Global Health, China (TGI China) welcomed world prominent clinician-scientist Professor Craig Anderson as the Deputy Director to lead and reinforce its academic development.

Dr. Anderson is currently Professor of Stroke Medicine and Clinical Neuroscience in the Sydney Medical School at the University of Sydney, and a Senior Principal Research Fellow of the National Health and Medical Research Council.  He has stepped down as Head of the Neurology Department at Royal Prince Alfred Hospital, a premier teaching hospital in Sydney, to take on this new role and has been Senior Director of the Neurological and Mental Health Division of The George Institute for Global Health, Australia.

“China, as one of the most dynamic developing countries, is also facing a huge burden from chronic diseases, in particular acute stroke.  I am honored to take on this position and expect to have more interactions with TGI China and Chinese stakeholders, clinicians, researchers, and industry,” said Professor Anderson. “The George Institute devotes itself to improving the health and wellbeing of peoples’ lives worldwide. China is definitely a key focus of the Institute’s activities and there is enormous potential for the Institute to help improve its healthcare system and performance.”

Professor Anderson has received Research Excellence awards from Royal Prince Alfred Research, University of Sydney, and the Stroke Society of Australasia (SSA). He is a member of several specialist societies, an Editor for the Cochrane Stroke Group, and former President of SSA and the Asia Pacific Stroke Organisation (APSO).

He continues to lead several major international studies on stroke, hypertension, and cardiovascular medicine for both the Institute as well as George Clinical, the commercial branch of the Institute. For instance, he is Principal Investigator of the INTERACT study, a large global trial with significant involvement of China, that indicated that early intensive blood pressure control improves recovery from hemorrhagic stroke which is very common in Asian people.  Further, he is soon to announce results of the ENCHANTED trial that involved over 3000 patients with acute ischemic stroke in an evaluation of a lower dose of the clot-busting drug alteplase with the potential to improve safety and effectiveness. He has published widely on the clinical and epidemiological aspects of stroke, cardiovascular disease and aged care, with over 300 original research papers and many presentations and international conferences.

Professor Zhi-Jie Zheng, Executive Director of The George Institute, China, congratulated Professor Anderson in being on board and welcomed this strong step forward of TGI China in regard of research.

“Professor Anderson is widely acknowledged as a leader in his fields, he is also familiar with China and the Chinese academia.” He said, “Dr. Anderson will bring his academic leadership, his dedication to excellence, and his passion in research to TGI China. We very much look forward to enhancing TGI China’s research and impact with his involvement and support in the future.”